Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25871654 | 0.84 | CYP3A4 (0.49) | SIGMAR1ACHECYP3A4CYP1A2CYP2D6 | |
| SCHEMBL8570353 | 0.83 | CYP1A2 (0.42) | SIGMAR1FUCA1ARG1ARG2ACHE | |
| SCHEMBL16054301 | 0.83 | CYP1A2 (0.42) | SIGMAR1FUCA1ARG1ARG2ACHE | |
| SCHEMBL20895733 | 0.83 | CYP1A2 (0.42) | SIGMAR1FUCA1ARG1ARG2ACHE | |
| SCHEMBL3988127 | 0.78 | SIGMAR1 (0.43) | SIGMAR1FUCA1ARG1ARG2GAA | |
| SCHEMBL23478565 | 0.77 | FUCA1 (0.49) | SIGMAR1FUCA1ACHEALDH1A1 | |
| SCHEMBL4237484 | 0.77 | SIGMAR1 (0.46) | SIGMAR1FUCA1GAAACHECYP3A4 | |
| SCHEMBL4237488 | 0.77 | GAA (0.54) | SIGMAR1FUCA1GAAACHE | |
| SCHEMBL15939078 | 0.77 | FUCA1 (0.49) | SIGMAR1FUCA1ACHEALDH1A1 | |
| SCHEMBL16030681 | 0.76 | SIGMAR1 (0.44) | SIGMAR1FUCA1ARG1ARG2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197867-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210377495-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-10980815-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200330477-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200038409-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10463675-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3183247-B9 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3183247-B1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170239264-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3183247-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | Pfizer Inc (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-1615634-B1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2007-05-16 | — | — | EP | disclosed |
| EP-1615634-A1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089363-A1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | disclosed |
| EP-0413455-B1 | Azabicyclo quinolone carboxylic acids | PFIZER (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5391763-A | 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5266569-A | Azatricyclo carboxylic acids useful as anti-bacterial agents | PFIZER INC. (US) | 1993-11-30 | — | — | US | disclosed |
| US-5229396-A | Anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1991002526-A1 | AZABICYCLO QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| EP-0413455-A2 | Azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463675-B2 | Aminopyrimidinyl compounds | JAK2, JAK1, JAK3 | SIGMAR1 1113/4885FUCA1 4870/4885ARG1 215/4885 |
| US-11197867-B2 | Aminopyrimidinyl compounds | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 | SIGMAR1 249/4885FUCA1 2545/4885ARG1 913/4885 |
| US-10980815-B2 | Aminopyrimidinyl compounds | JAK2, JAK1, JAK3 | SIGMAR1 1113/4885FUCA1 4870/4885ARG1 215/4885 |
| US-20200330477-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 | SIGMAR1 249/4885FUCA1 2545/4885ARG1 913/4885 |
| US-20200038409-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | SIGMAR1 207/4885FUCA1 2858/4885ARG1 721/4885 |
| US-20170239264-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | SIGMAR1 207/4885FUCA1 2858/4885ARG1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.